Assessment of the effect of calcium dobesilate in experimental liver ischemia-reperfusion injury

Ulus Travma Acil Cerrahi Derg. 2018 Sep;24(5):391-397. doi: 10.5505/tjtes.2018.33238.

Abstract

Background: This study investigates the protective effect of calcium dobesilate (CaDob), an effective antioxidant and anti-inflammatory drug, on experimental liver ischemia-reperfusion injury (IRI).

Methods: Forty rats were divided into four groups. In Group 1, (sham), only hepatic pedicle was induced. In Group 2 (control), hepatic pedicle was reperfused for 90 min after being clamped for 60 min. No treatment was given in Group 1 and 2. In Group 3 (perioperative CaDob), 100 mg/kg CaDob was given 2 hours prior to the operation in which hepatic pedicle was reperfused for 90 min following a 60-min clamp. In Group 4 (preoperative CaDob), after 100 mg/kg/day CaDob was given for 10 days before the operation, hepatic pedicle was clamped for 60 min and reperfused for 90 minutes. At the end of these procedures, blood and liver tissue samples were collected for biochemical and histopathological assessment.

Results: Liver function tests and tissue oxidative stress parameters were significantly lower in the preoperative and perioperative treatment groups than the control group. Furthermore, it was observed that histopathological injury in the control group significantly decreased in both perioperative and preoperative treatment groups.

Conclusion: Calcium dobesilate demonstrated a significant hepatoprotective effect in terms of its antioxidant and anti-inflammatory effects.

MeSH terms

  • Animals
  • Antioxidants / pharmacology*
  • Calcium Dobesilate / pharmacology*
  • Liver / drug effects*
  • Liver Diseases / metabolism*
  • Oxidative Stress / drug effects
  • Rats
  • Reperfusion Injury / metabolism*

Substances

  • Antioxidants
  • Calcium Dobesilate